186 related articles for article (PubMed ID: 21415205)
1. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract.
Scavone P; Umpiérrez A; Maskell DJ; Zunino P
J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205
[TBL] [Abstract][Full Text] [Related]
2. Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract.
Scavone P; Rial A; Umpierrez A; Chabalgoity A; Zunino P
Microbiol Immunol; 2009 Apr; 53(4):233-40. PubMed ID: 19714860
[TBL] [Abstract][Full Text] [Related]
3. Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2018 Apr; 117():348-355. PubMed ID: 29452195
[TBL] [Abstract][Full Text] [Related]
4. Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.
Scavone P; Miyoshi A; Rial A; Chabalgoity A; Langella P; Azevedo V; Zunino P
Microbes Infect; 2007 Jun; 9(7):821-8. PubMed ID: 17540603
[TBL] [Abstract][Full Text] [Related]
5. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
[TBL] [Abstract][Full Text] [Related]
6. Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins.
Scavone P; Sosa V; Pellegrino R; Galvalisi U; Zunino P
Microbes Infect; 2004 Jul; 6(9):853-60. PubMed ID: 15374007
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P
FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373
[TBL] [Abstract][Full Text] [Related]
8. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
[TBL] [Abstract][Full Text] [Related]
10. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
11. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
Smith SN; Himpsl SD; Mobley HLT
Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507
[TBL] [Abstract][Full Text] [Related]
12. A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against Proteus mirabilis urinary tract infection in mice model.
Choubini E; Habibi M; Khorshidi A; Ghasemi A; Asadi Karam MR; Bouzari S
Mol Immunol; 2018 Apr; 96():88-97. PubMed ID: 29525454
[TBL] [Abstract][Full Text] [Related]
13. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
14. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with proteus toxic agglutinin, a hemolysin-independent cytotoxin in vivo, protects against Proteus mirabilis urinary tract infection.
Alamuri P; Eaton KA; Himpsl SD; Smith SN; Mobley HL
Infect Immun; 2009 Feb; 77(2):632-41. PubMed ID: 19029299
[TBL] [Abstract][Full Text] [Related]
16. New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection.
Zunino P; Geymonat L; Allen AG; Preston A; Sosa V; Maskell DJ
FEMS Immunol Med Microbiol; 2001 Aug; 31(2):113-20. PubMed ID: 11549418
[TBL] [Abstract][Full Text] [Related]
17. Construction of an MR/P fimbrial mutant of Proteus mirabilis: role in virulence in a mouse model of ascending urinary tract infection.
Bahrani FK; Massad G; Lockatell CV; Johnson DE; Russell RG; Warren JW; Mobley HL
Infect Immun; 1994 Aug; 62(8):3363-71. PubMed ID: 7913698
[TBL] [Abstract][Full Text] [Related]
18. Vaccines in prophylaxis of urinary tract infections caused by the bacteria from the genus Proteus.
Drzewiecka D; Lewandowska G
Postepy Hig Med Dosw (Online); 2016 Sep; 70(0):1032-1043. PubMed ID: 27708208
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic Escherichia coli and Proteus mirabilis in a UTI mouse model.
Habibi M; Asadi Karam MR; Bouzari S
Int Immunopharmacol; 2015 Sep; 28(1):70-8. PubMed ID: 26033493
[TBL] [Abstract][Full Text] [Related]
20. MrpJ Directly Regulates Proteus mirabilis Virulence Factors, Including Fimbriae and Type VI Secretion, during Urinary Tract Infection.
Debnath I; Stringer AM; Smith SN; Bae E; Mobley HLT; Wade JT; Pearson MM
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30082479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
